![The F-35’s future: Can the fifth-gen fighter withstand political, technological headwinds? [Video]](https://breakingdefense.com/wp-content/uploads/sites/3/2024/04/240401_f35_clouds_8270083-scaled-e1711999276822.jpg?#)
Corcept unveils promising survival data from failed phase 2 ALS trial
Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering light by pointing to promising survival data.
Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering light by pointing to promising survival data.
